• Record: found
  • Abstract: found
  • Article: not found

Propranolol-resistant infantile haemangiomas.

The British Journal of Dermatology

Skin Neoplasms, Retrospective Studies, therapeutic use, Propranolol, drug therapy, Orbital Neoplasms, Male, Infant, Humans, Hemangioma, Female, Facial Neoplasms, Drug Resistance, Neoplasm, Child, Preschool, Antineoplastic Agents, Age of Onset

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Propranolol is now widely used to treat severe infantile haemangiomas (IHs). Very few cases of propranolol-resistant IH (PRIH) are mentioned in the literature. To describe the characteristics of PRIHs. A national, multicentre, retrospective, observational study was conducted from February 2011 to December 2011. All patients with PRIH evaluated by the members of the Groupe de Recherche Clinique en Dermatologie Pédiatrique from 1 January 2007 to 1 December 2011 were eligible. Among 1130 patients treated with propranolol for infantile haemangioma, 10 (0.9%) had PRIHs. Haemangioma propranolol resistance was observed at all ages during early childhood and at any proliferation stage. PRIH is a rare phenomenon that raises questions and merits further investigation. © 2013 British Association of Dermatologists.

      Related collections

      Author and article information



      Comment on this article